ÂÜÀòÂÒÂ×

Elizabeth has over 20 years of experience in biopharma and academia drug discovery and development. She is currently the chief Business Officer (CBO) of BigHat Biosciences, a company that integrates a wet lab for high-speed characterization with machine learning technologies to guide the search for better antibodies. She found her passion for pharmacology as a biologist in Merck Research Labs, later completing her doctorate in neuropharmacology at the University of Pennsylvania School of Medicine. After gaining growth, portfolio, and investment strategy experience at L.E.K. Consulting's Life Sciences practice, she transitioned to GlaxoSmithKline's R&D Strategy team. Following that, she was the Chief of Staff of Sanford Burnham Prebys Medical Research Institute, Head, Business Development at Axovant, and Chief Business Officer (CBO) at the New York Stem Cell Foundation (NYSCF) Research Institute. Elizabeth was part of the team to establish the collaboration with Cytovia to advance induced pluripotent stem cell (iPSC) NK cell therapies through GMP process development.